ClinicalTrials.gg
RecruitingNCT07716540Updated Oct 13, 2026

Analgesic Efficacy of Ultrasound-Guided Deep Iliacus Plane Block in Patients Undergoing Hip Fracture Surgery

An interventional study of Ultrasound-Guided Deep Iliacus Plane Block With Bupivacaine and Sham Deep Iliacus Plane Block With Normal Saline in Pain Management, sponsored by Kanuni Sultan Suleyman Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Kanuni Sultan Suleyman Training and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Hip fracture surgery is commonly associated with moderate to severe postoperative pain, which may delay mobilization and increase the need for opioid analgesics. The deep iliacus plane block is a recently described ultrasound-guided regional anesthesia technique designed to provide analgesia by allowing local anesthetic spread toward the femoral nerve, lateral femoral cutaneous nerve, and articular branches supplying the hip.

This prospective, randomized, double-blind, sham-controlled clinical trial will evaluate the analgesic efficacy of the deep iliacus plane block in adult patients undergoing hip fracture surgery under spinal anesthesia. After surgery, participants will be randomly assigned to receive either an ultrasound-guided deep iliacus plane block with local anesthetic or a sham block with normal saline.

All participants will receive standardized multimodal postoperative analgesia, including patient-controlled analgesia. The primary objective is to determine whether the deep iliacus plane block reduces postoperative opioid consumption during the first 24 hours after surgery. Postoperative pain scores, rescue analgesic requirements, sensory distribution, motor block, nausea and vomiting, quality of recovery, patient satisfaction, and block-related complications will also be evaluated.

Read the detailed description

This study is designed as a prospective, randomized, double-blind, sham-controlled clinical trial involving adult patients undergoing hip fracture surgery under spinal anesthesia.

Eligible participants will receive standard monitoring in accordance with the American Society of Anesthesiologists recommendations, including electrocardiography, noninvasive blood pressure measurement, and pulse oximetry. Spinal anesthesia will be performed under sterile conditions at the L3-L4 intervertebral level using 15 mg of isobaric bupivacaine.

Following completion of surgery, while the sensory effects of spinal anesthesia are still present, participants will be randomly allocated to one of two parallel study groups. Randomization will be performed using a computer-generated allocation sequence, and group assignments will be concealed using sequentially prepared sealed envelopes.

Participants assigned to the intervention group will receive an ultrasound-guided deep iliacus plane block on the surgical side. A low-frequency curvilinear ultrasound transducer will be positioned over the anterior hip region to identify the anterior inferior iliac spine, iliopubic eminence, iliopsoas muscle, psoas tendon, femoral nerve, and adjacent vascular structures. After identification of the target plane between the iliopsoas muscle and the anterior inferior iliac spine, a peripheral nerve block needle will be advanced using an in-plane approach. Following confirmation of appropriate needle-tip position, 30 mL of 0.25% bupivacaine will be administered.

Participants assigned to the control group will undergo an identical ultrasound-guided procedure and will receive 30 mL of normal saline as a sham block. Participants and postoperative outcome assessors will remain blinded to group allocation. The anesthesiologist performing the study intervention will not participate in postoperative outcome assessment.

All participants will receive a standardized multimodal postoperative analgesic regimen. Intravenous patient-controlled analgesia will contain tramadol at a concentration of 4 mg/mL, without a background infusion. The device will deliver 20 mg tramadol per patient-initiated bolus, with a 20-minute lockout interval and a maximum dose of 200 mg over four hours. Intravenous paracetamol 1 g will be administered routinely at the sixth postoperative hour. Intravenous dexketoprofen 50 mg will be provided as rescue analgesia when clinically required.

The primary outcome will be cumulative tramadol consumption during the first 24 postoperative hours. Pain intensity will be evaluated using the 0-10 Numerical Rating Scale, where 0 represents no pain and 10 represents the worst imaginable pain. Pain scores at rest and during movement will be recorded at predefined postoperative time points.

The sensory distribution of the block will be assessed approximately two hours after surgery, after resolution of the residual sensory effects of spinal anesthesia. Cold sensation will be evaluated using an alcohol-based swab over relevant lower-extremity and abdominal dermatomes. Participants will be asked to report any reduction, alteration, or loss of cold sensation compared with unaffected areas.

Additional outcomes will include rescue analgesic requirements, time to first rescue analgesia, patient-controlled analgesia demand frequency, presence and severity of motor block, postoperative nausea and vomiting, antiemetic requirements, block performance time, block-related complications, patient satisfaction, quality of recovery assessed using the Quality of Recovery-15 questionnaire at 24 hours, and duration of hospital stay.

The study aims to determine whether adding the deep iliacus plane block to standardized multimodal analgesia provides superior postoperative analgesia and reduces opioid requirements compared with standardized multimodal analgesia combined with a sham block.

02

Conditions studied

  • Pain Management
03

In context

Lead sponsor

Kanuni Sultan Suleyman Training and Research Hospital is the lead sponsor of 225 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Scheduled to undergo unilateral hip fracture surgery under spinal anesthesia
  • (ASA) physical status I-III
  • Ability to understand and use the Numerical Rating Scale and patient-controlled analgesia device
  • No to spinal anesthesia or the deep iliacus plane block
  • Written provided by the participant or legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • IV or higher
  • Emergency surgery
  • Coagulopathy, bleeding diathesis, or anticoagulant treatment that contraindicates spinal anesthesia or peripheral nerve block
  • Infection at the planned needle insertion site
  • Known allergy to local anesthetics or any study medication
  • Pre-existing peripheral neuropathy, neurological disorder, or motor deficit involving the operated lower extremity
  • Inability to understand or use the Numerical Rating Scale or patient-controlled analgesia device
  • Cognitive impairment or communication difficulty preventing reliable postoperative assessment
  • Refusal to participate
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    Deep Ilacus plane block group

    Participants assigned to this group will receive an ultrasound-guided unilateral deep iliacus plane block on the surgical side after completion of hip fracture surgery. The block will be performed using 30 mL of 0.25% bupivacaine. All participants will also receive standardized spinal anesthesia and multimodal postoperative analgesia, including intravenous patient-controlled analgesia with tramadol.

    Procedure: Ultrasound-Guided Deep Iliacus Plane Block With Bupivacaine

  • Placebo comparator
    Sham Control Group

    Participants assigned to this group will undergo an identical ultrasound-guided deep iliacus plane block procedure on the surgical side and will receive 30 mL of normal saline as a sham intervention. All participants will also receive standardized spinal anesthesia and the same multimodal postoperative analgesic regimen, including intravenous patient-controlled analgesia with tramadol.

    Procedure: Sham Deep Iliacus Plane Block With Normal Saline

Interventions

  • ProcedureUltrasound-Guided Deep Iliacus Plane Block With Bupivacaine

    Following completion of surgery, participants will receive an ultrasound-guided unilateral deep iliacus plane block on the surgical side. A low-frequency curvilinear ultrasound transducer will be used to identify the anterior inferior iliac spine, iliopsoas muscle, psoas tendon, femoral nerve, and adjacent vascular structures. A 22-gauge, 100-mm block needle will be advanced using an in-plane approach into the target plane between the iliopsoas muscle and the anterior inferior iliac spine. After confirmation of the appropriate needle-tip position, 30 mL of 0.25% bupivacaine will be administered.

  • ProcedureSham Deep Iliacus Plane Block With Normal Saline

    Participants will undergo an identical ultrasound-guided unilateral deep iliacus plane block procedure on the surgical side. The same anatomical landmarks, ultrasound approach, needle type, and target plane will be used. After confirmation of the appropriate needle-tip position, 30 mL of normal saline will be administered as the sham intervention.

06

What researchers measure

Primary outcomes

  1. Cumulative Tramadol Consumption During the First 24 Postoperative Hours

    The total amount of tramadol, expressed in milligrams, delivered by the intravenous patient-controlled analgesia device during the first 24 hours after surgery will be recorded. The patient-controlled analgesia solution will contain tramadol at a concentration of 4 mg/mL, with a 20 mg bolus dose, a 20-minute lockout interval, no background infusion, and a maximum limit of 200 mg over four hours. Lower cumulative consumption indicates a lower postoperative opioid requirement.

    Time frame: From completion of surgery to postoperative hour 24

Secondary outcomes

  1. Postoperative Numerical Rating Scale Pain Scores at Rest

    Postoperative pain intensity at rest will be assessed using an 11-point Numerical Rating Scale ranging from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain. Scores will be recorded separately at each predefined postoperative assessment time.

    Time frame: At postoperative hours 1, 6, 12, and 24

  2. Postoperative Numerical Rating Scale Pain Scores During Movement

    Postoperative pain intensity during movement will be assessed using an 11-point Numerical Rating Scale ranging from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain. Scores will be recorded separately at each predefined postoperative assessment time.

    Time frame: At postoperative hours 1, 6, 12, and 24

  3. Requirement for Rescue Analgesia During the First 24 Postoperative Hours

    The number and proportion of participants requiring at least one dose of rescue analgesia during the first 24 hours after surgery will be recorded. Intravenous dexketoprofen 50 mg will be administered as rescue analgesia when required despite the standardized multimodal analgesic regimen.

    Time frame: During the first 24 postoperative hours

  4. Cumulative Dexketoprofen Consumption During the First 24 Postoperative Hours

    The total amount of intravenous dexketoprofen administered as rescue analgesia during the first 24 hours after surgery will be recorded in milligrams. Each rescue dose will consist of 50 mg of intravenous dexketoprofen.

    Time frame: During the first 24 postoperative hours

  5. Dermatomal Distribution of Sensory Blockade Assessed by Cold Sensation

    The sensory distribution of the assigned intervention will be evaluated using a cold sensation test with ice cubes after the residual sensory effects of spinal anesthesia have resolved. Relevant lower-extremity and abdominal dermatomes will be assessed, and dermatomes showing reduced, altered, or absent cold sensation will be recorded.

    Time frame: At postoperative hour 2

  6. Incidence of Postoperative Nausea and Vomiting

    The occurrence of nausea, vomiting, or both during the first 24 hours after surgery will be recorded. Results will be reported as the number and proportion of participants experiencing at least one episode of postoperative nausea or vomiting.

    Time frame: During the first 24 postoperative hours, assessed at hours 1, 6, 12, and 24

  7. Quality of Recovery-15 Score at 24 Hours After Surgery

    Postoperative quality of recovery will be evaluated using the Turkish validated Quality of Recovery-15 questionnaire. The total questionnaire score will be recorded, with higher scores indicating better postoperative recovery.

    Time frame: At postoperative hour 24

  8. Incidence of Postoperative Motor Block

    Quadriceps muscle strength in the operated lower extremity will be assessed using a six-point Manual Muscle Testing scale based on the participant's ability to actively extend the knee: 0, no detectable quadriceps muscle activity; 1, trace muscle activity without joint movement; 2, active knee extension possible only with gravity eliminated; 3, active knee extension against gravity but not against external resistance; 4, active knee extension against gravity and moderate manual resistance; and 5, normal muscle strength against full manual resistance. Higher scores indicate better preservation of quadriceps motor function. Assessments will be performed by an outcome assessor masked to group allocation.

    Time frame: At postoperative hours 6 and 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — A final decision regarding the sharing of de-identified individual participant data has not yet been made. The decision will be made after completion of the study and publication of the primary results, taking into consideration participant confidentiality, ethics committee requirements, institutional policies, and applicable data protection regulations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartActual
Jul 20, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: date precision
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07716540
Responsible party
Engin Ihsan Turan (principal investigator, Kanuni Sultan Suleyman Training and Research Hospital) — Principal investigator
First posted
Jul 21, 2026
Start date
Jul 20, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Engin ihsan Turan, principal investigator
Contact
enginihsan@hotmail.com
+905382431114

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion